A comprehensive analysis of common cytogenetic abnormalities in multiple myeloma: from basic research to clinical applications - PubMed
5 hours ago
- #prognosis
- #cytogenetic abnormalities
- #multiple myeloma
- Multiple myeloma (MM) prognosis is significantly impacted by cytogenetic abnormalities.
- Study enrolled 52 newly diagnosed MM patients, detecting six common cytogenetic abnormalities.
- Abnormalities include RB1 deletion, D13S319 deletion, IGH translocation, 1q21 gain/amplification, P53 deletion, and 1p32 deletion.
- Positive detection rates of abnormalities ranged from 11.5% to 46.2%.
- Cytogenetic abnormalities linked to advanced tumor stage and adverse hematological parameters.
- Patients with abnormalities showed aggressive tumor behaviors like high proliferation index.
- All abnormalities except IGH translocation significantly shortened overall and progression-free survival.
- P53 deletion identified as an independent risk factor for overall survival.
- Patients with abnormalities had lower deep response rates to VRd induction therapy.
- 'Triple-hit' patients had shorter survival and reduced response rates compared to others.
- Combination of RB1 or D13S319 deletion with other high-risk indicators further shortened PFS.
- Findings support integrating cytogenetic markers for optimized risk stratification and personalized treatment.